Active Pharmaceutical Ingredient Market is Expected to Surpass US$ 42.5 Bn by 2025
An
active pharmaceutical ingredient is used in a finished pharmaceutical
product (FPP), intended to carry certain pharmacological actions or
otherwise have a direct effect in the diagnosis, cure, treatment,
mitigation or prevention of various diseases, or in some cases in
restoring, correcting or modifying human physiological functions. Sales
of pharmaceutical ingredient are on the rise due to a substantial
increase in high-potency API (HPAPI) and peptide API manufacturing. A
new study conducted by Persistence Market Research reveals that the US$
151.9 Bn global active pharmaceutical ingredient market will grow to US$
158.3 Bn by 2017 end, reflecting a Y-o-Y growth rate of 4.2%. This
market is estimated to further increase to US$ 225.2 Bn, expanding at a
CAGR of 4.5% over the forecast period (2016 – 2025)
PMR
in its report, titled “Active Pharmaceutical Ingredient Market – Global
Industry Analysis and Forecast, 2016 – 2025” has cited some of the key
factors prompting the global sales of API, which include:
Read Report Overview @ https://www.persistencemarketresearch.com/market-research/active-pharmaceutical-ingredient-market.asp
Higher
emphases on the development of novel therapeutics that contain
high-potency active pharmaceutical ingredients (HPAPIs). Ramped-up
investments from large-scale API manufacturers and contract
manufacturers in production of high potency API. The lower cost of labor
cost and abundance of raw materials continue to facilitate the growth
of API market in the Asia region. Faster approvals of API based peptide
and diabetes management drugs. Over the recent past, a range of peptide
drugs has been approved treatment of type 2 Diabetes Mellitus including
Albiglutide (GSK), Dulaglutide (Eli Lilly), Exenatide (Amylin
Pharmaceuticals) and Glucagon (Xeris Pharmaceuticals).
According
to the report, small molecule API type segment holds promising
investment opportunities for market participants on account of the
numerous off-patent events incurred in the last five years coupled with a
strong penetration of small scale manufacturers in Asia. On the basis
region, APAC’s API market was valued at US$ 61.4 Bn in 2016 and is
projected to witness the highest CAGR of 5.1 % during the forecast
period to reach a valuation of US$ 95.6 Bn. This is primarily owing to
the leadership of China and India in SMEs as well as their strong
distribution network in overseas markets especially in US, South Africa,
and Europe. Asian pharmaceuticals CMOs are competing on the basis of
cost and timeline for API manufacturing and are attracting U.S.-based
pharmaceuticals companies that are willing to outsource manufacturing
requirements. Meanwhile, Europe is projected to be the second fastest
growing market for API and is expected to reach US$ 42.5 Bn by 2025-end.
Manufacturers in Europe are prioritizing high-quality standards,
advanced manufacturing installations, and high purity of intermediates
(API).
Request Sample Report@ https://www.persistencemarketresearch.com/samples/11260
Johnson
Matthey, Siegfried, Almac, PolyPeptide Laboratories, AmbioPharm, Inc.,
Corden Pharma, Pepscan, BCN peptide, Provence Technologies Groups,
SennChemicals AG, Avecia OligoMedicines, Santaris Pharma - acquired by
Roche in 2014, ST Pharm Oligo Center, Cepia Sanofi, Biospring, Pfizer
CenterSource, Symbiotec Pharma Lab Pvt. Ltd., Gadea Grupo Farmacéutico,
STEROID S.p.A., Dolder AG, Dalton Pharma Services, FarmaBios Spa, Dextra
Laboratories Limited, GlycoSyn, Inalco Pharma, Sussex Research,
Pfanstiehl, Inc., Noramco, Inc., Johnson Matthey, Siegfried, Rhodes
Technologies, Ash Stevens, Fermion (public), FARMHISPANIA GROUP, Olon
SpA, Lonza Group are some of the leading companies operating in the
global active pharmaceutical ingredient market. Currently, many of the
pharmaceutical companies are focused on outsourcing of API manufacturing
to avoid large capital investments in setting up of API manufacturing
facilities. This has accelerated the demand for CMOs in API
manufacturing industry, which is dominated by small to medium
manufacturers.
Get Full Report now @ https://www.persistencemarketresearch.com/checkout/11260
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
Comments
Post a Comment